Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View Item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

Thumbnail
View/Open
Published version (693.2Kb)
Publication Date
2019-12
ICR Author
Yap, Christina
Author
O'Sullivan, JM
Hamblin, A
Yap, C
Fox, S
Boucher, R
Panchal, A
Alimam, S
Dreau, H
Howard, K
Ware, P
Cross, NCP
McMullin, MF
Harrison, CN
Mead, AJ
Type
Journal Article
Metadata
Show full item record
URL
https://repository.icr.ac.uk/handle/internal/3385
Collections
  • Clinical Studies
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1182/blood.2019001861
Subject
Humans
Hydroxyurea
Pyrazoles
Disease-Free Survival
Survival Rate
Risk Factors
Drug Resistance
Female
Male
Thrombocythemia, Essential
Research team
Clinical Trials & Statistics Unit
Language
eng
License start date
2019-12
Citation
Blood, 2019, 134 (23), pp. 2107 - 2111

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.